Rat and Mouse Model Market Size & Growth Forecast 2026–2035, By Segments (Model and Service, End-use, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Rat and Mouse Model Market size was over USD 2.29 Billion in 2025 and is likely to grow at a 9.1% CAGR between 2026 and 2035, attaining USD 5.47 Billion by 2035. The industry revenue for 2026 is assessed at USD 2.47 billion.
Get more details on this report
Request Free Sample ReportRat and Mouse Model Market Intelligence Snapshot
Regional Market Dynamics
- North America leads with 52.05% share due to strong pharmaceutical R&D concentration, advanced preclinical infrastructure, and consistent funding supporting widespread use across research institutions and drug discovery pipelines.
- Asia Pacific is expanding at 10.28% CAGR as biomedical research scales up, pharmaceutical development expands, and broader adoption of animal models strengthens early-stage and translational research workflows.
Segment Momentum
- The Model segment held an 84.17% share in 2025, supported by its essential role as the core research input for preclinical studies, disease investigation, and therapeutic testing.
- The Service segment is the fastest-growing area as organizations increasingly outsource breeding, customization, colony management, and study execution to improve flexibility and reduce internal infrastructure needs.
Market Expansion Drivers
- Increasing use of genetically engineered rodent models accelerating preclinical drug validation studies.
- Rising demand for humanized mouse models supporting precision medicine and oncology research.
- Expanding pharmaceutical R&D investment driving sustained demand for in vivo experimental platforms.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Prominent companies in the rat and mouse model market include Charles River Laboratories International, Inc. (United States), The Jackson Laboratory (United States), Taconic Biosciences, Inc. (United States), Labcorp Drug Development Inc. (United States), Inotiv, Inc. (United States), genOway S.A. (France), Janvier Labs (France), PerkinElmer, Inc. (United States), Transposagen Biopharmaceuticals, Inc. (United States), Biomere, Inc. (United States).Regional and Segment Outlook
North AmericaMarket Growth Drivers and Industry Trends
As drug developers push more targeted therapies into early-stage pipelines, the rat and mouse model market is seeing stronger demand for genetically engineered strains that can reproduce defined disease pathways with greater biological relevance than conventional models. Researchers use knockout, knock-in, and transgenic rodents to verify mechanism of action, assess target engagement, and identify safety liabilities before advancing compounds into costlier development stages. This transitions purchasing behavior toward specialized model providers, custom breeding services, and colonies with validated genetic backgrounds, contributing to market size growth through higher-value model sourcing and recurring use in preclinical study workflows.
Rising demand for humanized mouse models supporting precision medicine and oncology research
Precision medicine and immuno-oncology programs increasingly depend on humanized systems that can mimic human immune responses, making humanized strains a key source of market adoption in the rat and mouse model market. These models are particularly important when sponsors need to evaluate checkpoint inhibitors, cell therapies, tumor-immune interactions, or biomarker-linked treatment responses in settings that standard rodents cannot adequately represent. Their use is influencing procurement toward premium, technically complex models and associated services such as engraftment, validation, and colony management, driving market development as research teams prioritize translational relevance over lower-cost conventional alternatives.
Expanding pharmaceutical R&D investment driving sustained demand for in vivo experimental platforms
Broader pharmaceutical R&D spending is reinforcing market demand for dependable in vivo systems because larger and more diversified pipelines require continuous efficacy, toxicity, pharmacology, and disease progression studies. In practice, this means the rat and mouse model market benefits not only from higher study volumes but also from steadier ordering patterns tied to long development timelines and multi-program research portfolios. As biopharma companies expand internal discovery work and outsource portions of preclinical testing, model suppliers and contract research partners see sustained utilization of rodent platforms that remain central to candidate selection and go/no-go decision-making.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing use of genetically engineered rodent models accelerating preclinical drug validation studies | 2.00% | High | North America, Europe | High | Near Term |
| Rising demand for humanized mouse models supporting precision medicine and oncology research | 1.80% | High | North America, Asia Pacific | High | Mid Term |
| Expanding pharmaceutical R&D investment driving sustained demand for in vivo experimental platforms | 1.60% | Moderate | North America, Europe | High | Near Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America held a 52.05% share of the rat and mouse model market in 2025, backed by its dense concentration of pharmaceutical and biotechnology research activity, well-established preclinical testing infrastructure, and steady funding for disease modeling and drug discovery programs. The region’s leadership is reinforced by the routine use of rat and mouse models across academic laboratories, contract research settings, and commercial development pipelines, where demand is closely tied to ongoing work in oncology, immunology, and genetic research. This practical depth of usage sustains purchasing volumes for both standardized and specialized models while keeping utilization rates high across research institutions.
Asia Pacific is projected to expand at a 10.28% CAGR over the forecast period, with growth in the rat and mouse model market being impelled by the rising scale of biomedical research, expanding pharmaceutical development activity, and broader adoption of preclinical research tools across emerging and established research hubs. Demand is accelerating as more regional institutions and life sciences companies increase experimental capacity and integrate animal models into earlier-stage validation and translational research workflows. The region’s momentum reflects a widening research base that is converting into more consistent model procurement and usage across both public and private sector programs.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Regulatory Research StandardsGermany emphasizes high-quality laboratory animal models that comply with rigorous research and welfare standards. Demand remains focused on reproducible disease models supporting pharmaceutical development, toxicology, and academic biomedical research.
France 🇫🇷
Collaborative Research NetworksFrance supports the rat and mouse model market through collaborative biomedical research programs linking academic institutes and life science organizations. Standardized animal models remain central to drug discovery and disease mechanism studies.
Italy 🇮🇹
Preclinical Development FocusItaly prioritizes reliable rat and mouse models for preclinical validation across pharmaceutical and academic research. Institutions increasingly seek specialized models that improve study reproducibility and support evolving therapeutic development requirements.
Japan 🇯🇵
Disease Model InnovationJapan advances the rat and mouse model market through development of sophisticated genetic and disease-specific models. Research organizations increasingly adopt customized animal models to improve translational relevance across therapeutic research programs.
South Korea 🇰🇷
Biotechnology Research SupportSouth Korea expands demand for rat and mouse models through active biotechnology research and pharmaceutical innovation. Investment in genetically engineered models strengthens capabilities for oncology, immunology, and regenerative medicine investigations.
United States 🇺🇸
Translational Research HubThe U.S. rat and mouse model market is driven by sustained investment in translational research, gene-editing technologies, and preclinical drug development. Research institutions continue expanding demand for specialized disease models supporting precision medicine studies.
Segment Leadership and Growth Trends
Rat and Mouse Model Market Share (%), Model and Service, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportWithin the rat and mouse model market, the Model segment held the dominant position in 2025 with an 84.17% share. its position is underpinned by the central role that rat and mouse models play in preclinical research workflows, where direct access to established animal models remains foundational for study design, disease investigation, and therapeutic testing. Demand stays concentrated in this segment because models are the core research input, while purchasing decisions often prioritize strain availability, reproducibility, and suitability for specific experimental requirements.
The Service segment is emerging as the fastest-growing area of the rat and mouse model market as research programs increasingly require outsourced support tied to breeding, customization, colony management, and study execution. Its momentum is being influenced by the practical need to reduce internal infrastructure burden while maintaining research continuity and operational flexibility. Compared with relying only on in-house model capabilities, service-based engagement better fits organizations seeking specialized support and scalable execution across complex preclinical activities.
End-use Segment Analysis: Pharmaceutical & Biotechnology Companies (Largest Segment) vs Contract Research & Manufacturing Organizations (Fastest-Growing Segment)
Pharmaceutical & Biotechnology Companies accounted for the largest share of the rat and mouse model market in 2025. Their dominant position reflects steady use of rat and mouse models across drug discovery and preclinical development, where internal research pipelines depend on consistent access to validated experimental systems. This end-use segment maintains its share because these companies are direct sponsors of therapeutic research and therefore sustain recurring demand for models that support target validation, efficacy assessment, and early safety evaluation.
Contract Research & Manufacturing Organizations represent the fastest-growing end-use segment in the rat and mouse model market, supported by the broader shift toward outsourced research and development activities. Growth is strongest here because these organizations provide a practical extension of in-house capabilities for sponsors that want faster execution, flexible capacity, and access to specialized preclinical expertise without expanding fixed internal resources. Relative to other end users, their role grows as more research programs are structured around external partnerships for efficiency and operational scalability.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Model and Service | Model, Service | Model | Service |
| End-use | Pharmaceutical & Biotechnology Companies, Academic and Research Facilities, Contract Research & Manufacturing Organizations | Pharmaceutical & Biotechnology Companies | Contract Research & Manufacturing Organizations |
| Application | Cardiovascular Diseases, Genetic Diseases, Cancer, Infectious Diseases, Transplantation, Others | Cancer | Genetic Diseases |
Competitive Landscape and Market Positioning
1. Charles River Laboratories International Inc. (United States)
2. The Jackson Laboratory (United States)
3. Taconic Biosciences Inc. (United States)
4. Labcorp Drug Development Inc. (United States)
5. Inotiv Inc. (United States)
6. genOway S.A. (France)
7. Janvier Labs (France)
8. PerkinElmer Inc. (United States)
9. Transposagen Biopharmaceuticals Inc. (United States)
10. Biomere Inc. (United States)
The rat and mouse model market is advancing through improved preclinical research models that enhance drug discovery accuracy and biological relevance. Continuous innovation is strengthening genetic and disease modeling capabilities. Expanding research collaborations are also supporting more predictive biomedical studies.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Taconic Biosciences | May-23 | Taconic Biosciences introduced a new FcResolv NOG mouse model designed to improve long-term engraftment of human lymphoid cells. The development expands the company’s specialized research model portfolio, supporting advanced immunology and translational research applications in preclinical studies. |
| Taconic Biosciences | Nov-24 | Taconic Biosciences expanded its mouse model production and colony management services through a new facility on the U.S. West Coast. The expansion increases operational capacity and strengthens the company’s geographic footprint in research model supply and laboratory animal services. |
| Ozgene | Feb-23 | Ozgene was selected by the Animal Resources Centre to take over operations in Western Australia, including provision of mouse and rat research lines. The arrangement expands Ozgene’s regional service footprint and strengthens its role in genetically customized rodent model supply. |
| Harbour BioMed | Mar-25 | Harbour BioMed entered a global collaboration with AstraZeneca to develop multi-specific antibodies across immunology and oncology, including licensing access to its Harbour Mice antibody platform. The deal includes a USD 105 million equity investment, reinforcing platform commercialization and strengthening translational research capabilities. |
| Taconic Biosciences | Aug-23 | Taconic Biosciences signed an exclusive four-year agreement with Harlan Holdings granting breeding and distribution rights for its rat and mouse models in Israel. The arrangement provides royalty-based revenue and expands international commercialization of its research model portfolio. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Rat and Mouse Model Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Rat and Mouse Model Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchWhat is the market size of rat and mouse model?
How will the rat and mouse model industry grow in terms of size and CAGR by 2035?
How are genetically engineered rodent models changing preclinical validation strategies in the rat and mouse model market?
Why is demand for humanized mouse models and sustained pharmaceutical R&D investment strengthening in vivo research demand?
Why does the Model segment lead the rat and mouse model market?
How is the Service segment gaining momentum in this market?
Why does North America lead the rat and mouse model market?
What is driving Asia Pacific growth in the rat and mouse model market?
Which organizations are considered leaders in the rat and mouse model landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization